Fig. 1

Fig. 1. From: Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.

Pathways and opportunities to intervene in type 1 diabetes. This figure shows crucial pathways known to contribute to the pathogenesis of type 1 diabetes and relevant drugs for intervention. A key juncture is the antigen-presenting cell–T cell interaction, where activation of effector T cells can be prevented and generation of regulatory T cells (Tregs) can be enhanced. Another pivotal cell is the β cell itself. Augmentation of β cell mass or function along with prevention of apoptosis may be achievable goals. Most probably a combination of agents dampening inflammation, preventing effector cell activation, enhancing Tregs and augmenting β cell mass will be the ultimate solution for curing type 1 diabetes.

J B Matthews, et al. Clin Exp Immunol. 2010 May;160(2):176-184.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk